ArticleTherapeutic advances in medical oncology2023

Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT).

Louise Emmett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.